3rd Jun 2016 11:27
LONDON (Alliance News) - GlaxoSmithKline PLC said Friday that it will present data on two medicines in its immuno-inflammation portfolio, sirukumab and Benlysta, at the upcoming Annual European Congress of Rheumatology in London.
The congress takes place between June 8 and 11.
18 abstracts that will be presented or published will include data on the efficacy and safety of sirukumab in patients with active rheumatoid arthritis despite disease-modifying anti-rheumatic drug treatment, and efficacy and safety of Benlysta and standard care in patients with systemic lupus erythematosus.
"Immuno-inflammation is one of our six core areas of scientific research and development and we are progressing an exciting portfolio of antibodies and small molecules for several immune-mediated inflammatory diseases. Our research and development efforts cover several diseases including rheumatoid arthritis, systemic lupus erythematosus and primary membranous nephropathy which all have a debilitating impact on patients' lives," said Paul-Peter Tak, chief immunology officer and senior vice president of Glaxo's research and development pipeline.
Shares in Glaxo were up 1.9% at 1,472.00 pence Friday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline